Cybersecurity for:
Pharma & Biotechnology

Why is pharma a target for cyberattacks?

The pharmaceutical and biotechnology industry is a sector where intellectual property is worth billions. A new drug formula, clinical trial data, patent documentation — these are assets for which state-sponsored APT groups are willing to conduct multi-year espionage operations. The COVID-19 pandemic highlighted the scale of the threat when vaccine manufacturers became targets of Lazarus Group and APT29.

Simultaneously, pharmaceutical companies operate at the intersection of IT and OT — drug production lines are subject to rigorous GMP (Good Manufacturing Practice) requirements, and any interference with production parameters can result in entire product batches being recalled from the market.

Sector-specific challenges

Industrial espionage and IP theft

Phase III clinical trial data, active pharmaceutical ingredient (API) formulas, and regulatory documentation are the highest-value targets. APT groups employ advanced techniques: spear phishing on researchers, compromising CROs (Contract Research Organizations), and exfiltrating data from LIMS (Laboratory Information Management System) platforms.

GMP system integrity

Pharmaceutical production control systems must comply with GMP and 21 CFR Part 11 (electronic records and signatures). Manipulation of production parameters — temperature, humidity, dosing — can result in producing ineffective or dangerous drugs without visible signs of compromise.

Clinical trial data protection

Clinical trials generate massive volumes of sensitive data: patient medical records, test results, safety reports. GDPR and regulatory requirements (EMA, FDA) impose strict data protection obligations. A clinical data breach can not only result in fines but halt an entire research program.

How nFlo helps pharmaceutical companies

• Security audits — NIS2, GMP, and regulatory compliance assessment, IP protection gap identification
• SOC as a Service — 24/7 monitoring with data exfiltration and APT attack detection
• Penetration testing — testing LIMS systems, clinical trial portals, and production infrastructure

Key first steps

1. IP asset classification — identify and classify most valuable data (formulas, clinical data, patents)
2. Network segmentation — separate R&D network from production and administration
3. DLP and exfiltration monitoring — detect unauthorized copying of research data
4. Supply chain security — security audit of CROs and API suppliers

Schedule a free consultation — we will discuss the security of your pharmaceutical company.

Related Industries

• Cybersecurity for Healthcare
• Cybersecurity for Manufacturing & Industry